Rheumatology
Rheumatology guidance, immune pathway mechanisms, safety updates and trial intelligence across inflammatory arthritis and systemic autoimmune disease.
Latest Guidelines
Osteoporosis: risk assessment
Use the FRAX tool or DXA scan results to stratify fracture risk in adults aged 50+ with risk factors (prior fracture, corticosteroid use, family history, low…
2023 EULAR Recommendations for Systemic Lupus Erythematosus
This EULAR guideline addresses 2023 EULAR Recommendations for Systemic Lupus Erythematosus in Rheumatology. Use it to review current recommendation wording, eligibility criteria, and implementation considerations in…
2022 EULAR Recommendations for the Management of Rheumatoid Arthritis
This EULAR guideline addresses 2022 EULAR Recommendations for the Management of Rheumatoid Arthritis in Rheumatology. Use it to review current recommendation wording, eligibility criteria, and implementation…
2023 EULAR Recommendations for the Management of Gout
This EULAR guideline addresses 2023 EULAR Recommendations for the Management of Gout in Rheumatology. Use it to review current recommendation wording, eligibility criteria, and implementation considerations…
Osteoarthritis: Care and Management (NICE CG177)
Offer all patients with osteoarthritis structured information about self-management, weight management, and both land-based and aquatic exercise programmes as first-line treatment before considering pharmacological interventions. Use…
Systemic Lupus Erythematosus (BSR Guidelines)
Diagnose SLE using combination of clinical features plus positive ANA with anti-dsDNA or anti-Smith antibodies, and refer to rheumatology if SLE suspected Screen all newly diagnosed…
Trial Radar
A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive Participants With Active Psoriatic Arthritis
New drug icotrokinra tested against placebo for psoriatic arthritis in patients with and without previous biologic treatment.
TrialA Study of Guselkumab and Interleukin-17 (IL-17) Inhibitor Therapies in Participants With Psoriatic Arthritis in Routine Clinical Practice
This study compared how long patients stayed on guselkumab or IL-17 inhibitor treatments for psoriatic arthritis in routine…
PHASE3A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis
What is being tested: JNJ-78934804, a novel therapeutic agent, is being evaluated for efficacy and safety in treating…
PHASE1Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE Participants
Early-stage trial testing a new injection drug's safety, tolerability, and how the body processes it in patients with…
Clinical News
‘I’ve never been this good’ – revolutionary immune reset puts lupus in remission
Experimental immune reset treatment has induced drug-free remission in lupus patients during clinical trials, representing a significant advancement…
11 Jun 2026‘I’ve never been this good’ – revolutionary immune reset puts lupus in remission
Emerging immune reset therapy demonstrates potential to achieve drug-free remission in lupus patients, representing a significant shift from…
Relevant Mechanisms
CD20 B-cell Depletion
CD20 B-cell Depletion is a clinically relevant Drug Science explainer. CD20 is a non-glycosylated phosphoprotein expressed on the surface of…
MechanismIL-6 Signalling
IL-6 Signalling is a clinically relevant Drug Science explainer. Interleukin-6 (IL-6) is a pleiotropic cytokine with both pro-inflammatory and acute-phase…
MechanismJAK-STAT Pathway
JAK-STAT Pathway is a clinically relevant Drug Science explainer. The Janus kinase–signal transducer and activator of transcription (JAK-STAT) pathway is…
MechanismRANKL/Bone Remodelling
RANKL/Bone Remodelling is a clinically relevant Drug Science explainer. Bone remodelling is maintained by the tightly coupled activity of osteoblasts…
MechanismThe IL-17/IL-23 Axis
The IL-17/IL-23 Axis is a clinically relevant Drug Science explainer. The IL-23/IL-17 axis is a central driver of immune-mediated inflammatory…
CPD, Podcasts & Webinars
JAK Inhibitors: Updated Safety Signals, Patient Selection and Post-ORAL Surveillance
Recorded webinar focused on JAK inhibitors in rheumatology and immune-mediated inflammatory disease. Reviews JAK-STAT signalling, patient selection, ORAL…
podcastJAK Inhibitors: Updated Safety Signals, Patient Selection and Post-ORAL Surveillance
JAK inhibitors target the JAK-STAT pathway, interrupting intracellular cytokine signalling across several inflammatory diseases. ORAL Surveillance reshaped risk…
Follow Rheumatology safety updates
Get MHRA safety alerts and clinically relevant updates for this specialty in your ClinicaliQ digest.
Follow Rheumatology
Choose guideline, trial, Drug Science and education updates for this specialty.